IMA401 TCER
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IMA401 TCER, covering 2026-04-17 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor [Phase 1]